{"nctId":"NCT00197184","briefTitle":"Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared","startDateStruct":{"date":"2003-11-01"},"conditions":["Hepatitis B","Hepatitis A"],"count":276,"armGroups":[{"label":"Twinrix Junior","type":"EXPERIMENTAL","interventionNames":["Biological: Twinrix™ Junior"]},{"label":"Twinrix Adult","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Twinrix™ Adult"]}],"interventions":[{"name":"Twinrix™ Adult","otherNames":["Combined hepatitis A and B vaccine"]},{"name":"Twinrix™ Junior","otherNames":["Combined hepatitis A and B vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participation in primary study\n* Written informed consent obtained before each long term follow up visit.","healthyVolunteers":true,"sex":"ALL","minimumAge":"3 Years","maximumAge":"13 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Anti-hepatitis A (HAV) Antibody Concentrations","description":"Geometric mean concentration for anti-HAV antibodies expressed as Milli-International Units per milliliter (mIU/mL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1122.2","spread":null},{"groupId":"OG001","value":"1377.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"998.6","spread":null},{"groupId":"OG001","value":"1347.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"737.5","spread":null},{"groupId":"OG001","value":"915.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"576.8","spread":null},{"groupId":"OG001","value":"698.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-hepatitis B (HBs) Antibody Concentrations","description":"Geometric mean concentration for anti-HBs antibodies expressed as Milli-International Units per milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"479.9","spread":null},{"groupId":"OG001","value":"830.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"325.1","spread":null},{"groupId":"OG001","value":"695.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"270.2","spread":null},{"groupId":"OG001","value":"519.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150.2","spread":null},{"groupId":"OG001","value":"283.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-HAV Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.","description":"Any subjects becoming seronegative for anti-HAV antibodies (i.e. titres \\< 15 mIU/ml) at any long term time point, were to receive an additional vaccine dose administered between 6 to 12 months after Year 5 time point.","classes":[]},{"type":"PRIMARY","title":"Anti-HBs Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.","description":"Subjects losing seroprotective anti-HBs antibody titres (i.e. titres \\< 10 mIU/ml) at any long term time point, received an Engerix challenge dose. The table presents the geometric mean concentrations for anti-HBs antibodies, expressed as Milli-International Units per milliliter (mIU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"521.3","spread":null},{"groupId":"OG001","value":"509.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy.","description":"A serious adverse event (SAE) is any untoward medical occurrence that:\n\nresults in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited Local Symptoms","description":"Solicited local symptoms assessed include pain, redness and swelling at the vaccine injection site.\n\nAny= regardless of intensity grade; Grade 3 Pain= spontaneously painful","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited General Symptoms.","description":"Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms and headache.\n\nAny= regardless of intensity grade or relationship to vaccination; grade 3= prevented normal activity; Related= considered by the investigator to be causally related to the vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Receiving an Additional Vaccine Dose and Reporting Unsolicited Adverse Events (AEs).","description":"An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Receiving an Additional Vaccine Dose and Reporting Any Serious Adverse Events","description":"A serious adverse event (SAE) is any untoward medical occurrence that:\n\nresults in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":139},"commonTop":["Pain at the injection site","Headache","Fatigue","Gastrointestinal disorder","Arthralgia"]}}}